AGAnna Gavrieli

Anna Gavrieli

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Anna Gavrieli has a total of 7 co-authors. Here are the top co-authors by number of shared publications:

  • Christos S. Mantzoros

    Division of Endocrinology, Boston VA Healthcare System/Harvard Medical School

    1 shared publication
  • Freddy J. Alfaro

    Department of Neurology, Beth Israel Deaconess Medical Center, Harvard Medical School, 185 Pilgrim Road, Palmer 127, Boston, MA 02215, USA

    1 shared publication
  • Jagriti Upadhyay

    Division of Endocrinology, Beth-Israel Deaconess Medical Center/Harvard Medical School, Boston, MA, USA; Division of Endocrinology, Boston University Medical Center, Boston, MA, USA; Section of Endocrinology, Department of Medicine, VA Boston Healthcare System, Boston, MA, USA

    1 shared publication
  • Olivia M. Farr

    Division of Endocrinology, Diabetes and Metabolism, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA

    1 shared publication
  • Patricia Saade-Lemus

    Department of Neurology, Beth Israel Deaconess Medical Center, Harvard Medical School, 185 Pilgrim Road, Palmer 127, Boston, MA 02215, USA

    1 shared publication
  • Vasileios-Arsenios Lioutas

    Department of Neurology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA

    1 shared publication

Latest Publications

  • White matter microstructure and cognitive decline in metabolic syndrome: a review of diffusion tensor imaging

    by Freddy J. Alfaro, Anna Gavrieli, Patricia Saade-Lemus, Vasileios-Arsenios Lioutas, Jagriti Upadhyay, Vera Novak


  • Leptin applications in 2015

    by Olivia M. Farr, Anna Gavrieli, Christos S. Mantzoros

    Purpose of review To summarize previous and current advancements for leptin therapeutics, we described how leptin may be useful in leptin deficient states such as lipodystrophy, for which leptin was recently approved, and how it may be useful in the future for typical obesity. Recent findings The discovery of leptin in 1994 built the foundation for understanding the pathophysiology and treatment of obesity. Leptin therapy reverses morbid obesity related to congenital leptin deficiency and appears to possibly treat lipodystrophy, a finding which has led to the approval of leptin for the treatment of lipodystrophy in the USA and Japan. Typical obesity, on the other hand, is characterized by hyperleptinemia and leptin tolerance. Thus, leptin administration has proven ineffective for inducing weight loss on its own but could possibly be useful in combination with other therapies or for weight loss maintenance. Summary Leptin is not able to treat typical obesity; however, it is effective for reversing leptin deficiency-induced obesity and is possibly useful in lipodystrophy. New mechanisms and pathways involved in leptin resistance are continuously discovered, whereas the development of new techniques and drug combinations which may improve leptin's efficacy and safety regenerate the hope for its use as an effective treatment for typical obesity.